Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p>Robust population pharmacokinetic (PK) data for fluconazole are scarce. The variability of fluconazole penetration into the central nervous system (CNS) is not known. A fluconazole PK study was conducted in 43 patients receiving oral fluconazole (usually 800 mg every 24 h [q24h]) in combination with amphotericin B deoxycholate (1 mg/kg q24h) for cryptococcal meningitis (CM). A four-compartment PK model was developed, and Monte Carlo simulations were performed for a range of fluconazole dosages. A meta-analysis of trials reporting outcomes of CM patients treated with fluconazole monotherapy was performed. Adjusted for bioavailability, the PK parameter means (standard deviation) were the following: clearance, 0.72 (0.24) liters/h; volume of the central compartment, 18.07 (6.31) liters; volume of the CNS compartment, 32.07 (17.60) liters; first-order rate constant from the central to peripheral compartment, 12.20 (11.17) h<jats:sup>−1</jats:sup>, from the peripheral to central compartment, 18.10 (8.25) h<jats:sup>−1</jats:sup>, from the central to CNS compartment, 35.43 (13.74) h<jats:sup>−1</jats:sup>, and from the CNS to central the compartment, 28.63 (10.03) h<jats:sup>−1</jats:sup>. Simulations of the area under concentration-time curve resulted in median (interquartile range) values of 1,143.2 (range, 988.4 to 1,378.0) mg · h/liter in plasma (AUC<jats:sub>plasma</jats:sub>) and 982.9 (range, 781.0 to 1,185.9) mg · h/liter in cerebrospinal fluid (AUC<jats:sub>CSF</jats:sub>) after a dosage of 1,200 mg q24h. The mean simulated ratio of AUC<jats:sub>CSF</jats:sub>/AUC<jats:sub>plasma</jats:sub> was 0.89 (standard deviation [SD], 0.44). The recommended dosage of fluconazole for CM induction therapy fails to attain the pharmacodynamic (PD) target in respect to the wild-type MIC distribution for <jats:named-content content-type="genus-species">C. neoformans</jats:named-content>. The meta-analysis suggested modest improvements in both CSF sterility and mortality outcomes with escalating dosage. This study provides the pharmacodynamic rationale for the long-recognized fact that fluconazole monotherapy is an inadequate induction regimen for CM.</jats:p>

Original publication

DOI

10.1128/aac.00885-18

Type

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

18/06/2018

Volume

62